BRCA2 Variant Analysis Offers Insights Into Breast Cancer Risk and Treatment

By LabMedica International staff writers
Posted on 20 Nov 2026

Assessing inherited breast cancer risk can be challenging because different genetic variants may carry varying levels of risk. Harmful BRCA2 variants are generally associated with a 50% to 70% lifetime risk of breast cancer, influencing decisions about screening and prevention. However, new findings suggest that certain BRCA2 variants may confer a more moderate risk, highlighting the importance of more individualized genetic risk assessment.

Researchers at Mayo Clinic identified a group of hypomorphic BRCA2 variants associated with reduced penetrance, meaning they confer a lower risk of breast cancer than typical pathogenic BRCA2 variants. The study focused on 70 genetic variants that partially impair BRCA2 function rather than completely disrupting it. By examining their effects on gene activity alongside hereditary cancer testing data from a large patient population, researchers investigated how these variants influence inherited breast cancer risk.


Image Credit: iStock

The analysis estimated that individuals carrying these specific BRCA2 variants have a 20% to 25% lifetime risk of developing breast cancer, substantially lower than the risk generally associated with conventional pathogenic BRCA2 mutations. These findings suggest that variant-specific risk assessment could help clinicians tailor screening and prevention strategies more precisely. Although carriers may still qualify for regular mammography and breast magnetic resonance imaging (MRI), more accurate risk estimates could help inform decisions about preventive measures, including risk-reducing surgery.

The researchers also investigated whether tumors associated with hypomorphic BRCA2 variants might respond to PARP inhibitors, a class of targeted therapies that interfere with DNA repair mechanisms in cancer cells. The findings suggest that some tumors carrying these variants may retain sensitivity to PARP inhibition, potentially expanding treatment considerations for affected patients. However, tumor testing would be important to determine whether these therapies are appropriate in individual cases.

Published in Nature Communications on November 17, 2026, the study was conducted in collaboration with Ambry Genetics. Building on these findings, researchers are continuing to identify and characterize hypomorphic variants in both BRCA1 and BRCA2 to better understand their effects on inherited cancer risk. This work could help refine genetic counseling, personalize cancer prevention strategies, and inform treatment decisions for individuals carrying these variants.

“This shows that not all harmful BRCA2 variants carry the same level of breast cancer risk. Understanding these differences could help us better match cancer prevention and screening strategies to an individual's actual risk,” said Fergus Couch, Ph.D., a breast cancer researcher at Mayo Clinic Comprehensive Cancer Center. 

“Women and men who inherit these variants should benefit from risk management strategies tailored to the level of risk associated with the specific variant,” said Couch.

Related Links
Mayo Clinic Comprehensive Cancer Center


Latest BioResearch News